Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 1,457 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 1,457 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $29.95, for a total transaction of $43,637.15. Following the sale, the general counsel owned 18,086 shares in the company, valued at approximately $541,675.70. The trade was a 7.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stoke Therapeutics Stock Up 2.4%

NASDAQ:STOK traded up $0.74 during trading hours on Thursday, hitting $31.00. 1,946,301 shares of the stock traded hands, compared to its average volume of 698,331. Stoke Therapeutics, Inc. has a 1 year low of $11.17 and a 1 year high of $40.22. The company has a market cap of $1.93 billion, a price-to-earnings ratio of -11.03 and a beta of 1.17. The stock has a 50 day moving average price of $32.07 and a 200 day moving average price of $32.35.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.79) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.01. The business had revenue of $6.23 million for the quarter, compared to analysts’ expectations of $6.48 million. Stoke Therapeutics had a negative return on equity of 48.84% and a negative net margin of 529.20%. Equities analysts forecast that Stoke Therapeutics, Inc. will post -3.22 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Stoke Therapeutics by 5.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company’s stock valued at $162,000 after buying an additional 1,149 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Stoke Therapeutics by 21.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock valued at $11,053,000 after acquiring an additional 293,072 shares during the last quarter. Jane Street Group LLC boosted its position in shares of Stoke Therapeutics by 125.2% during the 1st quarter. Jane Street Group LLC now owns 26,978 shares of the company’s stock valued at $179,000 after acquiring an additional 15,001 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Stoke Therapeutics by 26.6% in the second quarter. JPMorgan Chase & Co. now owns 25,655 shares of the company’s stock valued at $291,000 after purchasing an additional 5,398 shares in the last quarter. Finally, Rhumbline Advisers grew its holdings in shares of Stoke Therapeutics by 33.9% in the second quarter. Rhumbline Advisers now owns 66,419 shares of the company’s stock valued at $754,000 after purchasing an additional 16,820 shares in the last quarter.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Weiss Ratings lowered shares of Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a report on Monday, May 11th. Wedbush boosted their target price on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a report on Tuesday, March 17th. BTIG Research restated a “buy” rating and set a $39.00 target price on shares of Stoke Therapeutics in a research report on Monday, May 11th. Chardan Capital restated a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, March 18th. Finally, Wall Street Zen cut shares of Stoke Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $41.83.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.